Drug Delivery of siRNA Therapeutics
Lamberti, Gaetano
Drug Delivery of siRNA Therapeutics - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 - 1 electronic resource (288 p.)
Open Access
The new frontier of pharmaceutical sciences is gene therapy, which is the use of molecules able to interact directly with the expression of the genetic material of the patient as well as of the disease-causing guest (bacteria, virus, parasites, and tumor cells). Among the molecules of interest for gene therapy, a relevant role is played by small interfering RNA (siRNA) molecules able to interfere with the expression of genes of interest for some diseases. However, siRNA molecules, even if they are powerful as drugs, are difficult to deliver since they are sensitive to enzymes present in plasma and they are large and negatively charged, so are difficult to administer into the cell nuclei, since the cell walls are scarcely permeable to large molecules and are also negatively charged. Therefore, the focus of research on siRNA-based therapies is their delivery, which can be performed by chemical modification, association with aptamers or polycations, or embedding them into properly designed liposomes. This book is centered on the more recent development in siRNA delivery techniques toward the clinical applications of this potent class of drugs.
Creative Commons
English
books978-3-03936-201-1 9783039362004 9783039362011
10.3390/books978-3-03936-201-1 doi
Medicine
oligonucleotide delivery light-activated release intracellular release liposome indocyanine green drug co-delivery methotrexate siRNA antitumor effect mixed micelles targeted delivery system cationic liposome folate folate receptor cationic cholesterol derivative siRNA delivery gene knockdown tumor-targeting VEGFA VEGFR1 endoglin peptide angiogenesis gene silencing migration proliferation endothelial cells RNAi therapeutics amphiphilic dendrons PAMAM dendrimers self-assembling nanovectors covalent dendrimers NABDs liposomes clinical trials drug delivery nanoparticle carbonate apatite ERBB2 AKT breast cancer ovarian cancer polymer lipid delivery poly(ethylene) imine PEI RNA tyrosine-modification tumor xenograft magnetic nanoparticle iron oxide BCL2 BIRC5/survivin oral cancer aptamers cancer nanoparticles STAT6 polyaspartamide pegylation polyamine polyplexes asthma n/a
Drug Delivery of siRNA Therapeutics - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 - 1 electronic resource (288 p.)
Open Access
The new frontier of pharmaceutical sciences is gene therapy, which is the use of molecules able to interact directly with the expression of the genetic material of the patient as well as of the disease-causing guest (bacteria, virus, parasites, and tumor cells). Among the molecules of interest for gene therapy, a relevant role is played by small interfering RNA (siRNA) molecules able to interfere with the expression of genes of interest for some diseases. However, siRNA molecules, even if they are powerful as drugs, are difficult to deliver since they are sensitive to enzymes present in plasma and they are large and negatively charged, so are difficult to administer into the cell nuclei, since the cell walls are scarcely permeable to large molecules and are also negatively charged. Therefore, the focus of research on siRNA-based therapies is their delivery, which can be performed by chemical modification, association with aptamers or polycations, or embedding them into properly designed liposomes. This book is centered on the more recent development in siRNA delivery techniques toward the clinical applications of this potent class of drugs.
Creative Commons
English
books978-3-03936-201-1 9783039362004 9783039362011
10.3390/books978-3-03936-201-1 doi
Medicine
oligonucleotide delivery light-activated release intracellular release liposome indocyanine green drug co-delivery methotrexate siRNA antitumor effect mixed micelles targeted delivery system cationic liposome folate folate receptor cationic cholesterol derivative siRNA delivery gene knockdown tumor-targeting VEGFA VEGFR1 endoglin peptide angiogenesis gene silencing migration proliferation endothelial cells RNAi therapeutics amphiphilic dendrons PAMAM dendrimers self-assembling nanovectors covalent dendrimers NABDs liposomes clinical trials drug delivery nanoparticle carbonate apatite ERBB2 AKT breast cancer ovarian cancer polymer lipid delivery poly(ethylene) imine PEI RNA tyrosine-modification tumor xenograft magnetic nanoparticle iron oxide BCL2 BIRC5/survivin oral cancer aptamers cancer nanoparticles STAT6 polyaspartamide pegylation polyamine polyplexes asthma n/a